Tirzepatide (Mounjaro / Zepbound) Dosing Tirzepatide is the weekly dual-hormone injection sold as Mounjaro for type 2 diabetes and Zepbound for obesity
The most plausible mechanism is the alteration in the calcium-dependent binding of the intrinsic factor and vitamin B12 complex with the receptors in the terminal ileum (174, 175)
For Zepbound (weight loss), coverage exists only if the employer specifically elected to include anti-obesity medications in their plan design
Your provider will use this information to determine whether Tirzepatide is appropriate and, if so, establish a starting dosage
(For small-molecule drugs like semaglutide, at least seven years must have passed from its FDA approval date to be eligible for selection, and for drugs with multiple FDA approvals, CMS will use the earliest approval date to make this determination.) If that happens, a negotiated Medicare price would be available beginning in 2027
Humana Medicare : Inclusion varies
